Disturbance of Vancomycin Infusion Flow during Multidrug Infusion: Influence on Endothelial Cell Toxicity.

human umbilical vein endothelial cells in vitro techniques infusions intravenous phlebitis simulation toxicity tests vancomycin

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
24 Dec 2021
Historique:
received: 11 11 2021
revised: 20 12 2021
accepted: 21 12 2021
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 22 1 2022
Statut: epublish

Résumé

Phlebitis is a common side effect of vancomycin peripheral intravenous (PIV) infusion. As only one PIV catheter is frequently used to deliver several drugs to hospitalized patients through the same Y-site, perturbation of the infusion flow by hydration or other IV medication may influence vancomycin exposure to endothelial cells and modulate toxicity. We assessed the toxicity of variations in vancomycin concentration induced by drug mass flow variations in human umbilical vein endothelial cells (HUVECs), simulating a 24 h multi-infusion therapy on the same line. Results were expressed as the percentage of viable cells compared with a 100% control, and the Kruskal-Wallis test was used to assess the toxicity of vancomycin. Our results showed that variations in vancomycin concentration did not significantly influence local toxicity compared to a fixed concentration of vancomycin. Nevertheless, the loss of cell viability induced by mechanical trauma mimicking multidrug infusion could increase the risk of phlebitis. To ensure that vancomycin-induced phlebitis must have other causes than variation in drug mass flow, further in vitro experiments should be performed to limit mechanical stress to frequent culture medium change.

Sections du résumé

BACKGROUND BACKGROUND
Phlebitis is a common side effect of vancomycin peripheral intravenous (PIV) infusion. As only one PIV catheter is frequently used to deliver several drugs to hospitalized patients through the same Y-site, perturbation of the infusion flow by hydration or other IV medication may influence vancomycin exposure to endothelial cells and modulate toxicity.
METHODS METHODS
We assessed the toxicity of variations in vancomycin concentration induced by drug mass flow variations in human umbilical vein endothelial cells (HUVECs), simulating a 24 h multi-infusion therapy on the same line. Results were expressed as the percentage of viable cells compared with a 100% control, and the Kruskal-Wallis test was used to assess the toxicity of vancomycin.
RESULTS RESULTS
Our results showed that variations in vancomycin concentration did not significantly influence local toxicity compared to a fixed concentration of vancomycin. Nevertheless, the loss of cell viability induced by mechanical trauma mimicking multidrug infusion could increase the risk of phlebitis.
CONCLUSION CONCLUSIONS
To ensure that vancomycin-induced phlebitis must have other causes than variation in drug mass flow, further in vitro experiments should be performed to limit mechanical stress to frequent culture medium change.

Identifiants

pubmed: 35052893
pii: antibiotics11010016
doi: 10.3390/antibiotics11010016
pmc: PMC8773181
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biomed Tech (Berl). 2015 Aug;60(4):365-76
pubmed: 26146091
Iran J Nurs Midwifery Res. 2019 Nov 07;24(6):432-436
pubmed: 31772917
Anesth Analg. 2009 Oct;109(4):1147-55
pubmed: 19762742
Sensors (Basel). 2012;12(9):12347-60
pubmed: 23112716
Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):694-700
pubmed: 25753888
Antimicrob Agents Chemother. 2015 Aug;59(8):4901-6
pubmed: 26055373
Anesth Analg. 2005 Apr;100(4):1048-1055
pubmed: 15781520
Clin Biochem. 1998 Nov;31(8):653-6
pubmed: 9876898
Int J Pharm. 2015 Jan 30;478(2):693-701
pubmed: 25510603
J Antimicrob Chemother. 1998 Feb;41(2):297-300
pubmed: 9533477
Toxicol In Vitro. 2004 Oct;18(5):703-10
pubmed: 15251189
Arch Toxicol. 2009 May;83(5):469-76
pubmed: 19052724
Medicine (Baltimore). 2020 Sep 18;99(38):e22376
pubmed: 32957416
Anesth Analg. 2012 Feb;114(2):328-32
pubmed: 22025488
J Hosp Infect. 2000 Nov;46(3):194-202
pubmed: 11073728
Antimicrob Agents Chemother. 2015 Feb;59(2):930-4
pubmed: 25421476

Auteurs

Maryline Drouet (M)

CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.

Elodie Cuvelier (E)

CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Feng Chai (F)

Institut National de la Santé et de la Recherche Médicale (INSERM) U1008, University of Lille, UFR3S, 1 Place de Verdun, F-59000 Lille, France.

Stéphanie Genay (S)

CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Pascal Odou (P)

CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Bertrand Décaudin (B)

CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Classifications MeSH